BioStem Technologies (BSEM) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
INmune Bio (INMB) has outperformed BioStem Technologies (BSEM) over the past year, losing 5.1% versus a loss of 50.5%. Over five years, BSEM leads with a +70.7% price change compared with -90.0% for INMB. INmune Bio is the larger company by market cap ($51.6 million vs $44.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSEM | INMB |
|---|---|---|
| Share price | $2.39 | $1.86 |
| Market cap | $44.63M | $51.62M |
| 1-day change | -3.24% | -0.53% |
| YTD return | -37.27% | +19.23% |
| 1-year return | -50.52% | -5.10% |
| 5-year return | +70.71% | -90.01% |
| P/E ratio (TTM) | 2.72 | — |
| Forward P/E | 8.24 | — |
| EPS (TTM) | $0.88 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $2.60 |
| 52-week low | $2.25 | $1.09 |
| Distance from 52-week high | -71.55% | -28.46% |
| Average volume | 120.39K | 416.29K |
| Shares outstanding | 18.67M | 27.75M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed BSEM by 45.4 percentage points over the past year.
BSEM vs INMB FAQ
Which is bigger, BioStem Technologies or INmune Bio?
INmune Bio (INMB) is larger, with a market capitalization of $51.62M compared with $44.63M for BioStem Technologies (BSEM).
Which stock has performed better over the past year, BSEM or INMB?
INMB returned -5.10% over the past 12 months, compared with -50.52% for BSEM (price return, excluding dividends). Past performance does not predict future results.
Are BioStem Technologies and INmune Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.